Rigel Pharmaceuticals | RIGL - Current Liabilities


Rigel Pharmaceuticals reported $94.4M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Agenus USD 249.24M 74.25M Mar/2026
Amgen USD 24.96B 534M Mar/2026
Anika Therapeutics USD 20.97M 942K Mar/2026
Arrowhead Research USD 295.22M 52.2M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Celldex Therapeutics USD 51.47M 481K Mar/2026
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Intrexon USD 23.02M 38K Jun/2024
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Ligand Pharmaceuticals USD 40.67M 3.22M Mar/2026
MacroGenics USD 95.94M 52.82M Mar/2026
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Veracyte USD 56.11M 3.82M Mar/2026